Paradigm Biocapital Advisors’s Kardigan Inc KARD Stock Holding History

Paradigm Biocapital Advisors’s Portfolio KARD Stock Details KARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Buy	+900,000	New	+$20.8M	0.4%	25

Other funds holding KARD

SCHF (GPE) Wilson, Wyoming $2.48B AUM 8.43% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

LMGAM

Liberty Mutual Group Asset Management Boston, Massachusetts $1.15B AUM 29.1% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Paradigm Biocapital Advisors's KARD Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in Kardigan Inc (KARD) in Q2 2026: 900,000 shares worth $21.5M. The stake represents 0.4% of the portfolio and ranks #25 among its holdings.

61 funds tracked by Wall St. Rank hold KARD as of Q2 2026.

Paradigm Biocapital Advisors held 900,000 shares of Kardigan Inc worth $21.5M as of Q2 2026.
Kardigan Inc was a new Paradigm Biocapital Advisors position in Q2 2026.
Kardigan Inc made up 0.4% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #25 holding.
61 funds tracked by Wall St. Rank held Kardigan Inc as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.